Does Rallies track congressional trades in VRTX?

Yes. Rallies tracks politician and congressional stock disclosures for VRTX, including reported purchases, sales, dates, owners, and trade amounts when available.

Is VRTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRTX. It does not provide personalized investment advice.

VRTX (Vertex Pharmaceuticals) Stock Analysis - Politician Trades

Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VRTX trades at $429.20 with a market cap of $110.81B and a P/E ratio of 25.21. VRTX moved -0.91% today. Year to date, VRTX is -4.09%; over the trailing twelve months it is -3.74%. Its 52-week range spans $362.50 to $519.88. Analyst consensus is strong buy with an average price target of $565.30. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded VRTX stock?

Recent politician trading activity in VRTX includes disclosures from David Taylor, David Taylor, Jefferson Shreve, Ro Khanna, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

VRTX Key Metrics

Key financial metrics for VRTX
Metric	Value
Price	$429.20
Market Cap	$110.81B
P/E Ratio	25.21
EPS	$17.01
Dividend Yield	0.00%
52-Week High	$519.88
52-Week Low	$362.50
Volume	1.43M
Avg Volume	0
Revenue (TTM)	$12.22B
Net Income	$4.34B
Gross Margin	86.24%

Congressional Trades in VRTX

David Taylor sale VRTX on Jan 29, 2026 (amount: $15.00K).
David Taylor purchase VRTX on Aug 7, 2025 (amount: $15.00K).
Jefferson Shreve purchase VRTX on Feb 24, 2025 (amount: $50.00K).
Ro Khanna purchase VRTX on Nov 15, 2024 (amount: $15.00K).
Ro Khanna purchase VRTX on Sep 9, 2024 (amount: $15.00K) for Spouse.

Latest VRTX News

JPMorgan Assigns Overweight to Vertex, Sets $515 PT on Renal Expansion — May 20, 2026
Vertex Pharmaceuticals Q1 EPS Hits $4.47 Despite $2.99B Revenue Miss, Barclays Sees 45% Upside — May 6, 2026
Vertex slides as Q1 revenue miss and reiterated 2026 outlook temper enthusiasm — May 5, 2026
Vertex Advances Stem-Cell Islet Therapy as BIP Wealth Adds $551,000 Stake — Apr 10, 2026
Vertex Licenses Halozyme’s Hypercon Platform for Three Targets with $15M Upfront — Apr 8, 2026

Recent VRTX Insider Trades

Bhatia Sangeeta N. sold 318 (~$134.75K) on May 4, 2026.
Liu Joy sold 1.10K (~$469.22K) on May 1, 2026.
Liu Joy sold 978 (~$439.29K) on Apr 1, 2026.

VRTX Analyst Consensus

23 analysts cover VRTX: 0 strong buy, 19 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $565.30.

Common questions about VRTX

Which politicians traded VRTX stock?: Recent politician trading activity in VRTX includes disclosures from David Taylor, David Taylor, Jefferson Shreve, Ro Khanna, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in VRTX?: Yes. Rallies tracks politician and congressional stock disclosures for VRTX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is VRTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRTX. It does not provide personalized investment advice.